Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (21907)	1/25/2000 9:25:00 AM
From: SSP	Read Replies (1) \| Respond to of 150070

SHMN - Metabolex Acquires Shaman Drug Development Program in Diabetes HAYWARD, Calif., Jan 25, 2000 (BW HealthWire) -- Metabolex, Inc. today announced that it has acquired materials and certain exclusive licenses to the diabetes drug discovery program of Shaman Pharmaceuticals, Inc. (OTCBB:SHMN) for use within specific geographic territories and therapeutic applications. The technology licensed by Metabolex includes the pharmaceutical development rights and some nutritional rights to a library of over 300 natural product extracts and compounds, many of which have demonstrated glucose lowering effects in animals. Shaman has retained all rights to its lead diabetes compound Masaprocol(TM). "We are very pleased to acquire this large library of natural product extracts which has been selected based on its glucose-lowering activity in animals," said Thomas Glaze, chief executive officer of Metabolex. "We plan to apply our own proprietary tools, assays and expertise in the field of diabetes research to identify, characterize and further develop those compounds offering the greatest promise as potential drug treatments for this serious and wide-spread disease." Shaman's diabetes research and development program was principally focused on the identification of orally active, blood-glucose lowering compounds to treat type 2 (adult onset or non-insulin dependent) diabetes. The company's compounds were identified from extracts derived from plants with a long history of medicinal use. Metabolex, Inc. is a privately held company founded to develop therapeutics for diabetes and related metabolic diseases. The company's goal is to combine its expertise in the biology of diabetes with a variety of technological approaches to develop proprietary treatments that affect the principal causes of the disease. Metabolex has three principal pharmaceutical research and development efforts. Metabolex's lead program is focused on MBX-102, a proprietary compound that has promising glucose lowering activity in animals. The second program focuses on Glucose Transport Signal Transduction pathways. Metabolex has partnered the diabetes aspects of this program to Abbott Laboratories as the keystone of its major pharmaceutical discovery in diabetes. Metabolex's third pharmaceutical program, partnered with the Parke-Davis Pharmaceutical Research Division of Warner-Lambert is a genomics-based program aimed at developing drugs to affect the abnormalities of insulin-producing beta cells in type 2 diabetes. The company's nutritional program, centered on its Insulin Potentiating Factor, has been licensed to Ross Laboratories, a Division of Abbott Laboratories. Copyright (C) 2000 Business Wire. All rights reserved. Distributed via COMTEX. -0- CONTACT: Metabolex Thomas A. Glaze, 510/293-8800 (CEO) David W. Pritchard, 510/293-8800 (V.P. & CFO)